Titolo:	MK1045-008 "A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK-1045 (Bispecific antibody antiCD19-antiCD3) Monotherapy or in Combination with Other Anticancer Agents in Participants with Non-Hodgkin Lymphoma"
Patologia:	Linfoma non Hodgkin
Tipo di Studio:	Prospettico
Fase:	1b/2
Principali criteri di inclusione:	• Has a confirmed diagnosis of FL Grade 1 to 3A. • Participants with FL who are R/R to systemic therapy (including an anti-CD20 mAb ± chemotherapy, or immunomodulatory agents). • Participants with FL who have experienced disease progression after CD19-targeting. • 2. Has radiographically measurable disease per Lugano Response Criteria, as verified by BICR, and meets the following criteria: FDG-avid, defined as 4-5 on a 5-point scale (as described in Appendix 13) - At least 1 nodal lesion (nonirradiated) that is >1.5 cm in the long axis, regardless of length of the short axis AND/OR extranodal lesion of >1.0 cm in the long axis.
Principali criteri di esclusione:	• Participants with FL who have transformed to a more aggressive type of lymphoma.
Sede e contatti	Istituto Nazionale Oncologico Candiolo, Via della Ricerca, 7, 10060 Candiolo (TO) umberto.vitolo@inoc.it simone.morabito@inoc.it